

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. whether they were unilateral, bilateral, or multilateral. It provides information about the location and geography of the ceasefire: the ceasefire's content (eq, what acts will be included and when it will start), with a link to a statement if one publicly exists: some indication of the conflict context; and links to previous ceasefires and peace agreements available on the PA-X Peace Agreement Database. Importantly, the tracker enables ceasefires to be viewed alongside COVID-19 infection and death data pulled in real-time from the application programming interface of the Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard.³ The ceasefire tracker is available free-of-charge in three different views: a filterable timeline of ceasefires, a searchable database, and a map view in which the COVID-19 death and infection rates can be toggled on and off.

Several aspects of the tracker shed light on the relationship between the pandemic and conflict resolution efforts (appendix). Notably, the UN Secretary General's global call was not a game changer in terms of conflict globally: despite initial ceasefire responses, the number of ceasefire declarations has decreased over time and fewer ceasefires are referencing COVID-19. Non-state armed actors have disproportionately responded, often with unilateral ceasefires that have not been reciprocated, sometimes for strategic reasons such as raising their profile internationally. However, in some areas where infection rates are high (eq, northern Syria), humanitarian ceasefires have been called.4

The ceasefire tracker forms part of a growing number of trackers that track not just health data relating to the pandemic, but also social science data focused on the political fall out of the virus, such as conflict patterns or civic freedom—which themselves will have public health consequences. It forms part of the University of Edinburgh's growing PeaceTech approach to harnessing data and technology innovation to support peacebuilding initiatives and illustrate how data from different expert domains and of different types can be integrated and visualised.⁵

We are grateful to our partners at mediatEUr, the Centre for Security Studies at ETH Zurich, Peace Research Institute Oslo, Conciliation Resources, Information Services (University of Edinburgh), the United States Institute of Peace, and the Mediation Unit of the UN Department of Political and Peacekeeping Affairs. The tracker received funding support from the Foreign, Commonwealth and Development Office (FCDO) through an initiative called the Covid Collective. The FCDO had no input into the tracker's conception, design, or substance, and neither the tracker nor this Correspondence reflect the FCDO's views. DB reports grants from Horizon 2020, outside the submitted work.

John Allison, Sanja Badanjak, Benjamin Bach, *Christine Bell, Devanjan Bhattacharya, Fiona Knaussel, Laura Wise christine.bell@ed.ac.uk

Information Services (JA), Political Settlements Research Programme, School of Law (SB, CB, DB, FK, LW), and School of Informatics (BB), University of Edinburgh, Edinburgh EH8 9YL, UK

- The Lancet. Violent conflict and health. Lancet 2010. https://www.thelancet.com/ series/violent-conflict-and-health (accessed Nov 7, 2020).
- United Nations. Global ceasefire. https://www.un.org/en/globalceasefire (accessed Nov 7, 2020).
- 3 Dong E, Du H, Gardner L. An interactive webbased dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20: 533–34.
 - Thompson TJ. Searching for COVID-19 ceasefires: conflict zone impacts, needs, and opportunities. Sept 15, 2020. https://www.usip. org/publications/2020/09/searching-covid-19ceasefires-conflict-zone-impacts-needs-andopportunities (accessed Nov 7, 2020).
 - Political Settlements Research Programme. Peacebuilding through technology: crafting digital platforms to facilitate peace. https://www.politicalsettlements. org/2019/07/13/peace-through-technology (accessed Nov 30, 2020).

5

Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products

The persistent worsening of the COVID-19 pandemic demands greater efforts for epidemiological

surveillance.^{1,2} Few studies have assessed the seroprevalence of anti-SARS-CoV-2 antibodies in the general population. These studies have generally had small sample sizes or been restricted to specific, well-defined individuals.^{3,4} Given that more than 1000 donors contribute to a plasma pool, the antibody profile of the pool could be considered a representation of the epidemiological status of the population at the time of donation.

In May, 2020, Grifols established a programme for continuous monitoring with ELISA⁵ of the fractionation plasma pools collected in Spain, Germany, Czech Republic, Slovakia, and the USA to track the incorporation of anti-SARS-CoV-2 antibodies into these pools and, consequently, into the resulting batches of intravenous immunoglobulin (IVIG). The first pools testing positive for anti-SARS-CoV-2 antibodies in plasma collected in Spain and the USA were detected from July to early September, 2020 (appendix pp 1-2). From mid-September to November, 2020, most pools in both countries were positive for anti-SARS-CoV-2 antibodies, with increased titres compared with earlier in the pandemic. By contrast, the first plasma pool to test positive for anti-SARS-CoV-2 antibodies in central European countries was detected in mid-November, 2020 (appendix p 3). This difference might reflect a different epidemiological status of the population in Germany, Czech Republic, and Slovakia compared with Spain and the USA.

The anti-SARS-CoV-2 antibody titres measured in the final IVIG products are also shown in the appendix (pp 1–2). Specific anti-SARS-CoV-2 antibodies were first detected in batches of IVIG products manufactured from plasma collected in the USA in September, 2020, with increased titres observed in October, 2020. Plasma from the USA is placed on an inventory hold for 60 days for traceability purposes. In addition, there is a span of 1–2 months between plasma For the **Ceasefires in a Time of COVID-19 tracker** see https:// pax.peaceagreements.org/static/ covid19ceasefires

See Online for appendix

See Online for appendix



Published Online February 16, 2021 http://dx.doi.org/10.1016/ \$1473-3099(21)00059-1 pool preparation and the release of manufactured IVIG.

These results suggest that plasma pools for fractionation might mirror the immunogenic status of the general population regarding SARS-CoV-2. Consequently, anti SARS-CoV-2 antibodies are being increasingly integrated into therapeutic IVIG products and, presumably, into intramuscular and subcutaneous immunoglobulin products. Since these products are indicated for immunodeficient patients and other therapeutic or prophylactic approaches, a close follow-up of the progression of the presence of anti-SARS-CoV-2 antibodies in both plasma pools and IgG products is recommended.

All authors are employees of Grifols, a manufacturer of IVIG products and other blood plasma derivatives.

*Carolina Romero, José María Díez, Rodrigo Gajardo

carolina.romero@grifols.com

Immunotherapies Unit, Bioscience Research & Development, Scientific Innovation Office, Grifols, Barcelona, Spain

- Guthmiller JJ, Wilson PC. Remembering seasonal 1 coronaviruses. Science 2020; 370: 1272-73.
- Ng KW, Faulkner N, Cornish GH, et al. 2 Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 2020; 370: 1339-43
- Pollán M, Pérez-Gómez B, Pastor-Barriuso R, 3 et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020; 396: 535-44
- Eckerle I, Meyer B. SARS-CoV-2 seroprevalence in 4 COVID-19 hotspots. Lancet 2020; 396: 514-15.
- Díez JM, Romero C, Gajardo R. Currently 5 available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy 2020; 12: 571-76.



S1473-3099(21)00060-8

Diagnostic dilemma in COVID-19-associated Published Online pulmonary aspergillosis March 1, 2021 http://dx.doi.org/10.1016/

We thank the community for rapid recognition and characterisation of COVID-19-associated pulmonary aspergillosis (CAPA), increasingly observed in people with severe SARS-CoV-2 infection. Consistent

with previous efforts to standardise definitions for invasive fungal infections,1-3 Philipp Koehler and colleagues⁴ propose new definitions for CAPA and provide management recommendations. We have questions and concerns for feedback.

Although we agree that standardised definitions are necessary to facilitate enrolment into clinical trials, consensus definitions for invasive fungal infections were historically supported by observational studies and not intended to guide clinical care.^{1,2} As a newly recognised syndrome, we worry that the proposed definitions for CAPA are not adequately supported by evidence; premature confidence in definitions risks biasing outcomes of future research and directing inappropriate management, without first establishing a requisite level of evidence.

The proposed CAPA definitions are highly reliant on bronchoscopy, which is variably used, especially in surge conditions with strained infection control. A bronchoscopy-driven approach will inevitably underestimate the burden of CAPA and potentially skew trial enrolment towards people with more invasive disease.

Also, we have concerns with the biomarker cutoffs proposed. Whereas investigators have done detailed studies to determine cutoffs for galactomannan enzyme immunoassays using appropriate measures (ie, receiver operating characteristic curves) in other populations,^{3,5} we are not aware of similar data to support recommendations for positivity at the multiple levels proposed by Koehler and colleagues, combined with requirements for repeated testing. This expert proposal is particularly problematic when cutoffs are not aligned with local regulatory recommendations. Should clinicians and investigators ignore their regulatory-cleared biomarker cutoffs in the absence of supportive evidence? Moreover, Koehler and colleagues proposed various cutoffs

for non-bronchoalveolar lavage biomarkers, which have not been cleared or validated. Although this proposal is reasonable to generate data in early research settings, one can hardly say that we have enough evidence to derive consensus.

Multiple issues arise with using definitions in different clinical and research contexts. For instance, conservative definitions are not actionable for clinical care or prevention studiessettings where the earliest therapy is essential to improve clinical outcomes. We thank our colleagues for early efforts to understand and define this new entity, but fear that more caution is needed to acknowledge critical gaps in data. We believe that establishing consensus definitions for CAPA requires more efforts, especially those directed towards deriving biomarker performance characteristics.

NP reports grants from Health System Research Institute and Cystic Fibrosis Foundation, and personal fees from Shionogi, outside the submitted work. JM reports personal fees and non-financial support from MSD, Pfizer, Gilead, Cidara, F2G, Scynexis, and Bio-Rad, and grants from Pfizer and Gilead, outside the submitted work. KAM reports personal fees from Cidara, Sfunga, and MSD, outside the submitted work, and patents on fungal diagnostics with royalties paid by MycoMed Technologies.

*Nitipong Permpalung, Johan Maertens, Kieren A Marr npermpa1@jhmi.edu

Departments of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA (NP, KAM); Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (NP); Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium (JM)

- 1 De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Disease Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
- Donnelly JP, Chen SC, Kauffman CA, et al. 2 Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2019: 71: 1367-76.
- Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6: 782-92.